The PD-1/PD-L1 pathway, as the final rate-limiting step of the antitumor immune response, can effectively block the inhibitory regulation of immune checkpoints and strengthen the antitumor immune response, which brings new hope for the treatment of patients with advanced NSCLC (25). The gene discussed is CD274; the disease is non-small cell lung carcinoma.